TY - JOUR
T1 - Use of hemoglobin for delivering exogenous carbon monoxide in medicinal applications
AU - Taguchi, Kazuaki
AU - Maruyama, Toru
AU - Otagiri, Masaki
N1 - Funding Information:
This work was supported, in part, by a Grant-in-Aid for Young Scientist (B) from the Japan Society for the Promotion of Science (JSPS) (KAKENHI 26860121).
Publisher Copyright:
© 2020 Bentham Science Publishers.
PY - 2020
Y1 - 2020
N2 - Carbon Monoxide (CO), at low concentrations, can have a variety of positive effects on the body including anti-apoptosis, anti-inflammatory, anti-oxidative and anti-proliferative effects. Although CO has great potential for use as a potent medical bioactive gas, for it to exist in the body in stable form, it must be associated with a carrier. Hemoglobin (Hb) represents a promising material for use as a CO carrier because most of the total CO in the body is stored associated with Hb in red blood cells (RBC). Attempts have been made to develop an Hb-based CO carrying system using RBC and Hb-based artificial oxygen carriers. Some of these have been reported to be safe and to have therapeutic value as a CO donor in preclinical and clinical studies. In the present review, we overview the potential of RBC and Hb-based artificial oxygen carriers as CO carriers based on the currently available literature evidence for their use in pharmaceutical therapy against intractable dis-orders.
AB - Carbon Monoxide (CO), at low concentrations, can have a variety of positive effects on the body including anti-apoptosis, anti-inflammatory, anti-oxidative and anti-proliferative effects. Although CO has great potential for use as a potent medical bioactive gas, for it to exist in the body in stable form, it must be associated with a carrier. Hemoglobin (Hb) represents a promising material for use as a CO carrier because most of the total CO in the body is stored associated with Hb in red blood cells (RBC). Attempts have been made to develop an Hb-based CO carrying system using RBC and Hb-based artificial oxygen carriers. Some of these have been reported to be safe and to have therapeutic value as a CO donor in preclinical and clinical studies. In the present review, we overview the potential of RBC and Hb-based artificial oxygen carriers as CO carriers based on the currently available literature evidence for their use in pharmaceutical therapy against intractable dis-orders.
KW - Anti-apoptosis
KW - Anti-proliferative effects
KW - Carbon monoxide
KW - Hemoglobin
KW - Hemoglobin-based oxygen carriers
KW - Red blood cell
UR - http://www.scopus.com/inward/record.url?scp=85086101368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086101368&partnerID=8YFLogxK
U2 - 10.2174/0929867325666181113122340
DO - 10.2174/0929867325666181113122340
M3 - Article
C2 - 30421669
AN - SCOPUS:85086101368
VL - 27
SP - 2949
EP - 2963
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 18
ER -